BioSpace News Archive

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced a $5.0 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency and the Defense Health Agency to fund a planned Phase 1b study of zotatifin as an anti-viral agent in an outpatient setting for those with mild to moderate COVID-19 disease.

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced that it has timely filed a nonprovisional patent application in the form of a PCT in the United States for its COVID-19 treatment under development.

More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studies

Neoleukin Therapeutics, Inc., “Neoleukin”, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat during the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 10:15 a.m. Eastern Time.

Yumanity Therapeutics, a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m. ET.

Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry’s first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), will report financial results for the first quarter ended March 31, 2021, on Monday, May 10, 2021.

the Epilepsy Foundation announced a collaboration with Eisai Inc. to develop a new platform — the Epilepsy Digital Experience Navigator — designed to empower people with epilepsy, their caregivers, and clinicians to use data to better understand and improve the epilepsy journey.

Micro Medical Solutions (MMS), an emerging leader in the treatment of CLTI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its MicroStent vascular stent

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 55,300 shares of Karyopharm’s common stock to seven newly-hired employees, with a grant date of April 30, 2021.

twoXAR, Inc., a Delaware corporation focused on discovering and bringing first-in-class small molecules to market, today announced that the company will rebrand as Aria Pharmaceuticals.